Mira Pharmaceuticals reports positive Phase 1 results for Ketamir-2 trial

Investing.comMonday, September 22, 2025 at 11:44:39 AM
Mira Pharmaceuticals reports positive Phase 1 results for Ketamir-2 trial
Mira Pharmaceuticals has announced promising Phase 1 results for its Ketamir-2 trial, marking a significant step forward in drug development. This trial's success could pave the way for new treatment options, potentially benefiting patients with conditions that Ketamir-2 aims to address. The positive results not only highlight the efficacy of the drug but also reflect the company's commitment to advancing healthcare solutions.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Actuate reports positive survival data for pancreatic cancer drug
PositiveFinancial Markets
Actuate has announced promising survival data for its pancreatic cancer drug, marking a significant advancement in treatment options for this challenging disease. This news is crucial as pancreatic cancer has one of the lowest survival rates among cancers, and effective therapies are desperately needed. The positive results from the clinical trials could lead to new hope for patients and their families, potentially changing the landscape of pancreatic cancer treatment.
Roche’s giredestrant shows positive results in advanced breast cancer trial
PositiveFinancial Markets
Roche's giredestrant has demonstrated promising results in a clinical trial for advanced breast cancer, marking a significant advancement in treatment options for patients. This development is crucial as it offers hope for improved outcomes in a disease that affects millions worldwide, highlighting Roche's commitment to oncology and innovation.
C4 Therapeutics' myeloma drug shows 50% response rate in trial
PositiveFinancial Markets
C4 Therapeutics has announced promising results from its clinical trial for a new myeloma drug, which demonstrated a 50% response rate among participants. This is significant as it highlights the potential for new treatment options in a disease that often has limited effective therapies. The success of this trial could pave the way for further development and approval, offering hope to patients and their families.
Latest from Financial Markets
Thoma Bravo to Buy PROS Holdings in $1.4 Billion Deal
PositiveFinancial Markets
Thoma Bravo's acquisition of PROS Holdings for $1.4 billion marks a significant move in the software industry, highlighting the growing interest in tech companies by private-equity firms. This deal not only reflects the value of PROS Holdings but also indicates a robust market for software solutions, which are increasingly vital for businesses aiming to enhance their operations.
Reeves claims Gatwick second runway ‘will mean cheaper holidays’; Trump’s $100,000 H-1B visa fee expected to hurt US growth – business live
PositiveFinancial Markets
The approval of a second runway at Gatwick Airport is being hailed as a positive development, with proponents like Rachel Curley from the Prospect union suggesting it could lead to cheaper holidays for travelers. This expansion is expected to boost the local economy and create jobs, despite concerns raised by critics like Green Party's Zack Polanski, who calls it a disaster. The debate highlights the balance between economic growth and environmental impact, making it a significant topic in the ongoing discussion about infrastructure development in the UK.
Robert Jenrick Net Worth: Inside His Life Of Power, Politics, and Privilege
NeutralFinancial Markets
Robert Jenrick, a prominent figure in UK politics, has garnered attention not just for his political career but also for his substantial net worth. This article delves into his life, exploring how his wealth intersects with his role in government. Understanding Jenrick's financial background is crucial as it sheds light on the influence of wealth in politics and raises questions about privilege and power dynamics within the UK government.
Jim Cramer on a Potential Mamdani Administration
NeutralFinancial Markets
Jim Cramer recently shared his thoughts on the possibility of a Zohran Mamdani administration in New York during an episode of Odd Lots. He expressed skepticism about the city becoming like San Francisco under Mamdani's leadership. This commentary is significant as it reflects the ongoing discussions about the direction of New York's political landscape and the potential impact of new leadership.
Over 70% of H-1B visa holders are Indian citizens. Its government says Trump jacking the fee to $100,000 is ‘likely to have humanitarian consequences’
NegativeFinancial Markets
The Indian government has expressed serious concerns over the recent decision to increase the H-1B visa fee to $100,000, a move that could have significant humanitarian consequences. With over 70% of H-1B visa holders being Indian citizens, this policy change could impact thousands of professionals seeking opportunities in the U.S. Additionally, the Chinese community, which constitutes about 12% of visa holders, may also feel the effects. This situation highlights the ongoing challenges faced by skilled workers in navigating immigration policies.
Strive to buy Semler Scientific in merger of Bitcoin treasuries
PositiveFinancial Markets
Strive, co-founded by former GOP presidential candidate Vivek Ramaswamy, is making headlines with its recent merger with Semler Scientific, a small tech company that went public on Nasdaq in September. This merger is significant as it highlights the growing intersection of technology and finance, particularly in the realm of Bitcoin treasuries. It reflects a strategic move to enhance Strive's portfolio and could potentially lead to innovative developments in the tech sector.